Ramadan Fasting in a Patient with Chronic Myeloid Leukemia Receiving Nilotinib as Upfront-Reference-Cited by-同舟云学术

Ramadan Fasting in a Patient with Chronic Myeloid Leukemia Receiving Nilotinib as Upfront

Published:2020-06-15 Issue:2 Volume:13 Page:664-667
ISSN:1662-6575
Container-title:Case Reports in Oncology
language:en
Short-container-title:Case Rep Oncol

Author:

Al-Dubai Husam N.,Yassin Mohammed A.,Abdulla Mohammed A.,Aldapt Mahmood S.,Ghassoub Rola S.

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm classically described as triphasic disease: chronic, accelerated, and blast crisis. There are many unmet needs and unanswered questions about CML. Intermittent fasting in patients with CML on tyrosine kinase inhibitors is among these unmet needs. Here we report the effect of intermittent fasting on response to nilotinib as upfront in a 49-year-old female Muslim who fasted during Ramadan and took her medication once instead of twice daily and remained in major molecular response.

Publisher

S. Karger AG

Subject

Oncology

Reference2 articles.

1. Al-Dewik NI, Morsi HM, Samara MM, Ghasoub RS, Gnanam CC, Bhaskaran SK, et al. Is adherence to imatinib mesylate treatment among patients with chronic myeloid leukemia associated with better clinical outcomes in Qatar? Clin Med Insights Oncol. 2016 Oct 2;10:95–104.

2. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22(5):935–42.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ramadan fasting in health and disease (2020): A narrative review;Ibnosina Journal of Medicine and Biomedical Sciences;2021